EMA Authorised: Xospata (gilteritinib fumarate) — Astellas Pharma Europe B.V.

View source ↗

Summary

The EMA authorised Xospata (gilteritinib fumarate) for acute myeloid leukemia; the marketing authorization holder is Astellas Pharma Europe B.V. Decision date: …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Xospata (gilteritinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Astellas Pharma Europe B.V.. Decision date: 27/06/2024. Orphan medicine